Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Financing Activities (2020 - 2025)

Foghorn Therapeutics has reported Cash from Financing Activities over the past 6 years, most recently at $581000.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $581000.0 for Q4 2025, up 14425.0% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 99.03% YoY), and the annual figure for FY2025 was $1.0 million, down 99.03%.
  • Cash from Financing Activities for Q4 2025 was $581000.0 at Foghorn Therapeutics, up from $49000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for FHTX hit a ceiling of $103.2 million in Q2 2024 and a floor of $4000.0 in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was $293500.0 (2022), compared with a mean of $6.6 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 99.93% in 2022 and later surged 100100.0% in 2024.
  • Foghorn Therapeutics' Cash from Financing Activities stood at $21.7 million in 2021, then plummeted by 99.93% to $16000.0 in 2022, then surged by 1062.5% to $186000.0 in 2023, then tumbled by 97.85% to $4000.0 in 2024, then skyrocketed by 14425.0% to $581000.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $581000.0 (Q4 2025), $49000.0 (Q3 2025), and $254000.0 (Q2 2025) per Business Quant data.